Impact of RFA on Esophageal Distensibility and Mucosal Impedance
Start Date
8/19/2025
Completion Date
7/31/2027
Summary
Patients undergoing ablative therapy for management of dysplastic Barrett's Esophagus (BE) will have decreased distensibility over the course of treatment, but improvement in mucosal impedance as BE epithelia is replaced by neosquamous epithelia. This information may lead to further research in predicting therapeutic response and complications. The purpose of this research is to collect information while measuring changes related to the esophagus in patients that receive radiofrequency ablation (RFA) for dysplastic Barrett's Esophagus (BE) or esophageal cancer. Study participation includes measurements of the esophagus with the use of two different devices. This takes place during clinically indicated upper endoscopies during the timeframe the participant is receiving RFA treatments. This process will take up to an additional 10 minutes during the upper endoscopy and be done while the participant is sedated.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Radiofrequency ablation alone
Conditions
Locations
Mayo Clinic
Rochester, Minnesota 55905
United States